{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:25:31Z","timestamp":1786980331888,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23gm1210012p0204"],"award-info":[{"award-number":["23gm1210012p0204"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K08012"],"award-info":[{"award-number":["21K08012"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognosis of metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with liver fibrosis. We aimed to investigate whether liver stiffness measurement (LSM) and changes in LSM (\u0394LSM) on magnetic resonance elastography (MRE) can predict clinical events in patients with MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 405 patients with MASLD who underwent at least two MREs. The patients were divided into five groups corresponding to fibrosis stages (0\u20134) based on initial LSM and classified as progressors (\u0394LSM\u2009\u2265\u200919%) or non-progressors (\u0394LSM\u2009&lt;\u200919%) based on the difference between the first and last LSM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean follow-up period was 72.6\u00a0months, and the mean interval between MREs was 23.5\u00a0months. There were 52 (12.8%) progressors and 353 (87.2%) non-progressors. The initial LSM was significantly associated with the cumulative probabilities of decompensated cirrhosis, hepatocellular carcinoma (HCC), liver-related events, extrahepatic malignancies, and overall mortality but not with cardiovascular disease. Progressors had significantly higher hazard ratios (HRs) for decompensated cirrhosis, HCC, and liver-related events but not for extrahepatic malignancies, cardiovascular disease, or overall mortality. Among patients without cirrhosis, the HR for developing cirrhosis among progressors was 60.15. Progressors had a significantly higher risk of liver-related events, even in the low initial LSM (fibrosis stage 0\u20132) subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both initial LSM and \u0394LSM can predict liver-related events in patients with MASLD, even for low initial LSM. This integrated assessment can allow more detailed risk stratification compared with single LSM assessments and identify high-risk patients with MASLD among those previously considered as low risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-023-02049-9","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T15:01:48Z","timestamp":1697468508000},"page":"56-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography"],"prefix":"10.1007","volume":"59","author":[{"given":"Takashi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7815-549X","authenticated-orcid":false,"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"2049_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","journal-title":"J Hepatol"},{"key":"2049_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"2049_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793\u2013801.","journal-title":"J Hepatol"},{"key":"2049_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-97.e10.","journal-title":"Gastroenterology"},{"key":"2049_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547\u201354.","journal-title":"Hepatology"},{"key":"2049_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","volume":"21","author":"CH Ng","year":"2023","unstructured":"Ng CH, Lim WH, Hui Lim GE, et al. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21:931-9.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2049_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cgh.2022.01.002","volume":"21","author":"H Fujii","year":"2023","unstructured":"Fujii H, Iwaki M, Hayashi H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol. 2023;21:370\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2049_CR8","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559\u201369.","journal-title":"N Engl J Med"},{"key":"2049_CR9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","volume":"150","author":"K Imajo","year":"2016","unstructured":"Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150:626-37.e7.","journal-title":"Gastroenterology"},{"key":"2049_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","volume":"17","author":"C Hsu","year":"2019","unstructured":"Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019;17:630-7.e8.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2049_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","volume":"18","author":"R Vuppalanchi","year":"2021","unstructured":"Vuppalanchi R, Noureddin M, Alkhouri N, et al. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2021;18:373\u201392.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2049_CR12","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","volume":"70","author":"J Jung","year":"2021","unstructured":"Jung J, Loomba RR, Imajo K, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut. 2021;70:1946\u201353.","journal-title":"Gut"},{"key":"2049_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","volume":"163","author":"V Ajmera","year":"2022","unstructured":"Ajmera V, Kim BK, Yang K, et al. Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants. Gastroenterology. 2022;163:1079-89.e5.","journal-title":"Gastroenterology"},{"key":"2049_CR14","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/liv.14593","volume":"40","author":"MAT Han","year":"2020","unstructured":"Han MAT, Vipani A, Noureddin N, et al. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: a multicenter study. Liver Int. 2020;40:2242\u201351.","journal-title":"Liver Int"},{"key":"2049_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/hep.32594","volume":"77","author":"T Gidener","year":"2023","unstructured":"Gidener T, Dierkhising RA, Mara KC, et al. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology. 2023;77:268\u201374.","journal-title":"Hepatology"},{"key":"2049_CR16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"2049_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/hep.32302","volume":"76","author":"N Kawamura","year":"2022","unstructured":"Kawamura N, Imajo K, Kalutkiewicz KJ, et al. Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2022;76:186\u201395.","journal-title":"Hepatology"},{"key":"2049_CR18","unstructured":"Quantitative Imaging Biomarker Alliance. QIBA profile: Magnetic resonance elastography of the liver. 2018. https:\/\/qibawiki.rsna.org\/images\/a\/a5\/MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf"},{"key":"2049_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.acra.2017.09.023","volume":"25","author":"NA Obuchowski","year":"2018","unstructured":"Obuchowski NA. Interpreting change in quantitative imaging biomarkers. Acad Radiol. 2018;25:372\u20139.","journal-title":"Acad Radiol"},{"key":"2049_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1148\/radiol.2017161398","volume":"285","author":"SD Serai","year":"2017","unstructured":"Serai SD, Obuchowski NA, Venkatesh SK, et al. Repeatability of MR elastography of liver: a meta-analysis. Radiology. 2017;285:92\u2013100.","journal-title":"Radiology"},{"key":"2049_CR21","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265\u201373.","journal-title":"J Hepatol"},{"key":"2049_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","volume":"8","author":"FE M\u00f3zes","year":"2023","unstructured":"M\u00f3zes FE, Lee JA, Vali Y, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:704\u201313.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2049_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/hep.32151","volume":"75","author":"T Gidener","year":"2022","unstructured":"Gidener T, Yin M, Dierkhising RA, et al. Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: a retrospective study. Hepatology. 2022;75:379\u201390.","journal-title":"Hepatology"},{"key":"2049_CR24","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70:1375\u201382.","journal-title":"Gut"},{"key":"2049_CR25","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","volume":"20","author":"K Imajo","year":"2022","unstructured":"Imajo K, Honda Y, Kobayashi T, et al. Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20:908-17.e11.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2049_CR26","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","volume":"152","author":"CC Park","year":"2017","unstructured":"Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152:598-607.e2.","journal-title":"Gastroenterology"},{"key":"2049_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","volume":"19","author":"S Petta","year":"2021","unstructured":"Petta S, Sebastiani G, Vigan\u00f2 M, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol. 2021;19:806\u201315.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2049_CR28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/liv.15555","volume":"43","author":"M Kugelmas","year":"2023","unstructured":"Kugelmas M, Noureddin M, Gunn N, et al. The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis. Liver Int. 2023;43:964\u201374.","journal-title":"Liver Int"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02049-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-02049-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02049-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T22:03:41Z","timestamp":1704319421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-02049-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2049"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-02049-9","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"1 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}